Midatech Pharma PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Midatech Pharma PLC
Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
A Chinese billionaire has invested in UK biotech Midatech and signed a licensing deal for an as yet unapproved carcinoid cancer drug, sending it much-needed backing just days after the company said it did not have enough cash to get it to the second half of the year.
The Oxford-based biotech needs more money and fast to fund development of MTD201, which it believes offers a number of competitive advantages over Novartis blockbuster Sandostatin LAR.
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- DARA BioSciences, Inc.
- MidaSol Therapeutics LP
- Midatech Group Ltd.
- Oncogenerix, Inc.
- Pharmida AG
- Point Therapeutics, Inc.